Parmax Pharma Share Price
Small Cap | Pharmaceuticals and health care | BSE: 540359
₹47.83 
4.33 (9.95 %)
Last Updated: 06 Feb 2025 04:01 PM
BEARISH
Overview
Open (₹) 47.82
High (₹) 47.84
Low (₹) 46.64
Prev. Close (₹) 43.50
Volume 1,562
VWAP (₹) 43.40
ROCE (%) -82.27
Industry P/E 47.39
TTM P/E -5.25
P/B Ratio 298.94
Market Cap (₹) Cr.17.89
Dividend Yield (%)--
EPS (₹) -11.33
ROE-7081.25%
Sales Growth (%) -28.34
Profit Growth (%)5,452.87
Day Range
47.8447.84
52 Week Range
24.1854.00
Historical Returns
Returns (6M)
43.81 %
Returns (1Y)
48.49 %
Returns (3Y)
-6.22 %
Returns (5Y)
153.07 %
Returns (6M)
43.81 %
Returns (1Y)
48.49 %
Returns (3Y)
-6.22 %
Returns (5Y)
153.07 %
SWOT Analysis
- Increasing Revenue every Quarter for the past 4 Quarters
- Strong short-term momentum: Price above short-term moving averages (EMA_10)
- Strong long-term momentum: Price above long-term moving averages (EMA_200)
- Positive ROC (9) indicates upward momentum.
- Strong trend indicated by ADX above 25.
- Price above the pivot point indicates bullish sentiment.
- Price above EMA and SMA (50) indicates bullish momentum.
Technicals
Technical Rating
BEARISHRSI 52.65
MFI 69.48
ATR 1.71
Commodity Channel Index 93.67
ROC125 24.21
ROC21 4.04
Williams %R -32.41
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 43.50 | 43.50 | 43.50 | 43.50 | 43.50 | 43.50 | 43.50 |
| Week Ago | 39.59 | 39.59 | 39.59 | 39.59 | 39.59 | 39.59 | 39.59 |
| Month Ago | 44.38 | 45.84 | 46.68 | 43.54 | 42.08 | 41.24 | 39.78 |
EMA & SMA
47.83
Current Price
Bullish Moving Averages
20
Bearish Moving Averages
0
5 Day 42.50
9 Day 41.38
10 Day 41.09
12 Day 40.27
14 Day 40.15
20 Day 41.10
26 Day 41.54
50 Day 43.60
100 Day 44.01
200 Day 38.43
Deals & Announcements
Bulk and Block Deals
Insider Trading
| Date | Name | Action | Avg. Price | Quantity | Deal Value |
|---|---|---|---|---|---|
| 19 Apr, 2022 | GOSALIA MEENA ALKESH | Acquisition | ₹ | 2,54,800 | BSE |
| 04 Dec, 2021 | PRAVINA MAHASUKHLAL GOPANI | Disposal | ₹ | 3,81,170 | BSE |
| 04 Dec, 2021 | VIPUL MAHASUKH GOPANI | Acquisition | ₹ | 3,81,170 | BSE |
| 08 Oct, 2021 | PRAVINA MAHASUKHLAL GOPANI | Disposal | ₹ | 3,81,170 | BSE |
| 08 Oct, 2021 | ALKESH M. GOPANI | Acquisition | ₹ | 3,81,170 | BSE |
| 24 Dec, 2020 | Pravina Mahasukhlal Gopani | Acquisition | ₹ | 7,48,260 | BSE |
Corporate Actions
No corporate actions available.
Announcements
| Date | Source | Detail |
|---|---|---|
| 04 Jan, 2025 | BSE India | Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2015 for the quarter ended on 31st December, 2024 received from M/S Purva Sharegistry India Pvt Ltd. Registrar and Share Transfer Agent of our company. |
| 02 Dec, 2024 | BSE India | we would like to inform you that the financial statements for the period ending on September 30, 2024 were duly prepared and approved at the scheduled meeting of Board of Directors held on Thursday, 14th November, 2024. We apologize for this delay in filing , due to circumstances beyond our control.\r\nWe request you to condone this delay filing as all processes and approvals were completed within the required timeline. |
| 15 Nov, 2024 | BSE India | As per regulation 30 and 33 of SEBI (LODR) Regulations, 2015 the board of directors at its meeting held on 14th November, 2024 inter alia considered and approved the Unaudited Financial Results for the quarter and half year ended on 30th September, 2024 along with the Limited Review Report provided by B A Shah S R Mehta, statutory Auditor of the company. |
| 15 Nov, 2024 | BSE India | Pursuant to the provisions of Regulation 30 and 33 of the SEBI (LODR) Regulations, 2015, the Board of Directors of the company at its meeting held on 14th November, 2024 inter alia has considered and approved the Unaudited Financial Results of the company for the quarter and half year ended on September, 30, 2024, B A Shah S R Mehta & Co. Statutory Auditors have carried out the limited review of the Unaudited Financial Results for the quarter and half year ended on 30.09.2024 and board has also taken on record their Limited Review Report on the said results. |
| 06 Nov, 2024 | BSE India | Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 ,inter alia, to consider and approve The meeting of the Board of Directors of PARMAX PHARMA LIMITED will be held on Thursday, 14th November, 2024 at 4.00 PM inter alia to consider, approve the Unaudited Financial Results for the Quarter ended on 30th September, 2024. |
| 10 Oct, 2024 | BSE India | The compliance certificate dated 1st October, 2024 under Regulation 74(5) of SEBI(DP) Regulations, 2018 for the quarter ended 30th September, 2024 received from M/S Purva Sharegistry India Pvt. Ltd. , Registrar and Share Transfer Agent of our company. |
| 02 Oct, 2024 | BSE India | Pursuant to Regulation 44(3) of SEBI (LODR), 2015; we hereby enclose the voting results of 30th Annual General Meeting held on Monday, 30th September, 2024 at 3.00 PM and consolidated Scrutinizer''s report pursuant to Section 108 of the Companies Act 2013 and Rule 20(4)(xii) of the Companies (Management and Administration) Rules, 2014. |
| 30 Sept, 2024 | BSE India | This is to inform you that the 30th Annual General Meeting of the PARMAX PHARMA LIMITED held today, 30th September, 2024 at 3.00 pm at the registered office of the company and the meeting concluded at 4.40 pm. |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 07 Nov, 2024 | 14 Nov, 2024 |
| Quarterly Results | -- | 07 Aug, 2024 | 14 Aug, 2024 |
| Audited Results | (Revised) | 30 May, 2024 | 30 May, 2024 |
| Audited Results | -- | 30 May, 2024 | 28 May, 2024 |
| Quarterly Results | -- | 08 Feb, 2024 | 14 Feb, 2024 |
| Quarterly Results | -- | 06 Nov, 2023 | 10 Nov, 2023 |
| Quarterly Results | -- | 09 Aug, 2023 | 14 Aug, 2023 |
| Audited Results | -- | 24 May, 2023 | 30 May, 2023 |
| Quarterly Results | -- | 07 Feb, 2023 | 11 Feb, 2023 |
| Quarterly Results | -- | 09 Nov, 2022 | 12 Nov, 2022 |
Share Holding Pattern
| Owner Name | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
|---|
About Parmax Pharma
Parmax Pharma is a Public Limited Listed company incorporated on 02/11/1994 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24231GJ1994PLC023504 and registration number is 023504. Currently Company is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 11.05 Cr. and Equity Capital is Rs. 4.45 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Not Applicable
Founded
1994
Managing Director
Dr. Umang Alkesh Gosalia
NSE Symbol
--
Parmax Pharma Management
| Name | Designation |
|---|---|
| Dr. Umang Alkesh Gosalia | Managing Director |
| Ms. Ami R Shah | Independent Director |
| Mr. Nikhil S Uchat | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| SunPhrmInds | ₹4,46,576.22 | ₹1,742.00  ₹1,752.75(-0.61%) | ₹1,249.800 - ₹1,960.200 |
| Divis Labora | ₹1,56,123.40 | ₹6,119.70 ₹6,123.50(-0.06%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,21,675.13 | ₹1,471.50  ₹1,436.80(2.42%) | ₹1,240.700 - ₹1,702.000 |
| ManKind Phar | ₹1,18,478.90 | ₹2,480.10 ₹2,483.00(-0.12%) | ₹1,910.100 - ₹3,050.000 |
| DrReddysLab | ₹1,15,939.04 | ₹1,236.65 ₹1,227.55(0.74%) | ₹1,104.690 - ₹1,420.200 |
FAQs on Parmax Pharma
What is the share price of Parmax Pharma?
The share price of Parmax Pharma on 06 Feb, 2025 is ₹ 47.83.
What is 52W high and 52W low share price of Parmax Pharma?
The highest and lowest 52W share prices of Parmax Pharma are ₹ 54.000 and ₹ 24.180
What is the market cap of Parmax Pharma?
The market capitalization of Parmax Pharma as of 06 Feb, 2025 is ₹ 17.89 Crores
What is the P/E ratio of Parmax Pharma?
The current P/E ratio of Parmax Pharma as of 06 Feb, 2025 is 47.39
What is the PB ratio of Parmax Pharma?
The PB ratio of Parmax Pharma as of 06 Feb, 2025 is 298.94
Top Gainers
948IHFL26I
IBHFL NCD186
₹845
₹705 (0.2%)
GREAVESCOT
Greaves
₹281.85
₹234.9 (0.2%)
ASHSI
Ashirwd Stl
₹45.66
₹38.05 (0.2%)
CAPRO
Caprola.Chem
₹62.4
₹52 (0.2%)
Top Losers
DHANBANK
Dhanalak.Bnk
₹32.19
₹35.97 (-0.11%)
08MPD
08MPD
₹8.66
₹9.62 (-0.1%)
BALTE
BalurghtTran
₹27.13
₹31.24 (-0.13%)
DARSHANORNA
Darshan Orna
₹4.57
₹5.07 (-0.1%)
Market Indices
Sensex
₹78,699.07
₹78,472.48 (0%)